PMVP
PMV Pharmaceuticals, Inc.
Price Chart
Latest Quote
$1.13
+0.03 (+2.73%)
Current Price
| Previous Close | $1.10 |
| Open | $1.11 |
| Day High | $1.15 |
| Day Low | $1.08 |
| Volume | 242,604 |
Stock Information
| Shares Outstanding | 53.33M |
| Total Debt | $293K |
| Cash Equivalents | $93.55M |
| Net Income | $-78.34M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $60.26M |
| EPS (TTM) | $-1.47 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-32.99M |
| Income | $-78.34M |
| Book/sh | $1.65 |
| Cash/sh | $1.75 |
| Employees | 54 |
Financial Ratios
| Quick Ratio | 10.88 |
| Current Ratio | 11.14 |
| Debt/Eq | 0.33 |
Returns & Margins
| ROA | -39.14% |
| ROE | -63.16% |
Ownership
| Insider Ownership | 3.35% |
| Institutional Ownership | 69.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.03 |
| P/B | 0.69 |
Analyst Data
| Recommendation | none |
| Target Price | $4.33 |
Technical Indicators
| SMA20 | $1.15 |
| SMA50 | $1.29 |
| SMA200 | $1.31 |
| RSI | 42.22 |
| ATR | 0.0620 |
| Shares Float | 43.14M |
| Short Float | 6.32% |
| Short Ratio | 8.43 |
| Volatility | 1.36 |
| Rel Volume | 0.92 |
Performance History
| Week | +3.67% |
| Month | -13.74% |
| Quarter | -24.67% |
| 6 Months | -4.24% |
| YTD | -8.13% |
| Year | +3.67% |
| 3 Years | -80.68% |
| 5 Years | -96.72% |
| 10 Years | -96.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.13 | 242,600 |
| 2026-06-17 | $1.10 | 200,400 |
| 2026-06-16 | $1.08 | 120,500 |
| 2026-06-15 | $1.06 | 197,900 |
| 2026-06-12 | $1.11 | 120,500 |
| 2026-06-11 | $1.09 | 368,400 |
| 2026-06-10 | $1.06 | 150,600 |
| 2026-06-09 | $1.05 | 226,500 |
| 2026-06-08 | $1.09 | 185,400 |
| 2026-06-05 | $1.12 | 319,600 |
| 2026-06-04 | $1.19 | 114,900 |
| 2026-06-03 | $1.16 | 269,900 |
| 2026-06-02 | $1.18 | 422,200 |
| 2026-06-01 | $1.23 | 443,300 |
| 2026-05-29 | $1.20 | 409,900 |
| 2026-05-28 | $1.19 | 478,100 |
| 2026-05-27 | $1.20 | 362,200 |
| 2026-05-26 | $1.23 | 248,800 |
| 2026-05-22 | $1.26 | 163,300 |
| 2026-05-21 | $1.28 | 204,600 |
| 2026-05-20 | $1.31 | 88,300 |
| 2026-05-19 | $1.31 | 580,100 |
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
đ° Latest News
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks âĸ 2026-06-10T13:35:02Z
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity
Insider Monkey âĸ 2026-06-02T13:56:39Z
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga âĸ 2026-05-13T21:06:19Z
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?
Simply Wall St. âĸ 2026-04-20T18:34:44Z
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
Motley Fool âĸ 2026-02-03T15:20:49Z
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
Motley Fool âĸ 2026-02-03T15:06:20Z
Caesarstone And 2 More Penny Stocks Worth Watching
Simply Wall St. âĸ 2026-01-29T18:05:18Z
Top Penny Stocks To Watch In November 2025
Simply Wall St. âĸ 2025-11-18T18:05:30Z
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2025-10-28T16:25:27Z
PMV Pharmaceuticals Says Updated Rezatapopt Data Show 46% Response Rate in Ovarian Cancer
MT Newswires âĸ 2025-10-24T16:29:59Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $86,206,000 | $85,448,000 | $80,132,000 | $77,040,000 |
| Other Income Expense | $-45,000 | $-16,000 | $3,000 | $87,000 |
| Other Non Operating Income Expenses | $-45,000 | $-16,000 | $3,000 | $87,000 |
| Net Non Operating Interest Income Expense | $6,337,000 | $10,655,000 | $11,171,000 | $3,627,000 |
| Operating Expense | $86,206,000 | $85,448,000 | $80,132,000 | $77,040,000 |
| General And Administrative Expense | $16,329,000 | $26,921,000 | $24,247,000 | $25,052,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Net Interest Income | $6,337,000 | $10,655,000 | $11,171,000 | $3,627,000 |
| Interest Income | $6,337,000 | $10,655,000 | $11,171,000 | $3,627,000 |
| Normalized Income | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Net Income From Continuing And Discontinued Operation | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Total Operating Income As Reported | $-86,206,000 | $-85,448,000 | $-80,132,000 | $-77,040,000 |
| Net Income Common Stockholders | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Net Income | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Net Income Including Noncontrolling Interests | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Net Income Continuous Operations | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Pretax Income | $-79,914,000 | $-74,809,000 | $-68,958,000 | $-73,326,000 |
| Interest Income Non Operating | $6,337,000 | $10,655,000 | $11,171,000 | $3,627,000 |
| Operating Income | $-86,206,000 | $-85,448,000 | $-80,132,000 | $-77,040,000 |
| Per Share | ||||
| Diluted EPS | $-1.48 | $-1.14 | $-1.44 | $-1.61 |
| Basic EPS | $-1.48 | $-1.14 | $-1.44 | $-1.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-86,073,000 | $-84,304,000 | $-78,875,000 | $-76,725,000 |
| Reconciled Depreciation | $133,000 | $1,144,000 | $1,257,000 | $315,000 |
| EBITDA (Bullshit earnings) | $-86,073,000 | $-84,304,000 | $-78,875,000 | $-76,725,000 |
| EBIT | $-86,206,000 | $-85,448,000 | $-80,132,000 | $-77,040,000 |
| Diluted Average Shares | $52,541,613 | $51,578,807 | $48,014,645 | $45,594,824 |
| Basic Average Shares | $52,541,613 | $51,578,807 | $48,014,645 | $45,594,824 |
| Diluted NI Availto Com Stockholders | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Tax Provision | $-2,172,000 | $-16,100,000 | $2,000 | $-9,000 |
| Research And Development | $69,877,000 | $58,527,000 | $55,885,000 | $51,988,000 |
| Selling General And Administration | $16,329,000 | $26,921,000 | $24,247,000 | $25,052,000 |
| Other Gand A | $16,329,000 | $26,921,000 | $24,247,000 | $25,052,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $104,712,000 | $176,080,000 | $225,689,000 | $246,028,000 |
| Total Assets | $116,562,000 | $191,288,000 | $252,152,000 | $270,308,000 |
| Total Non Current Assets | $1,335,000 | $15,630,000 | $44,743,000 | $23,302,000 |
| Other Non Current Assets | $297,000 | $235,000 | $190,000 | $313,000 |
| Investmentin Financial Assets | $0 | $13,843,000 | $25,505,000 | $2,495,000 |
| Current Assets | $115,227,000 | $175,658,000 | $207,409,000 | $247,006,000 |
| Other Current Assets | $2,284,000 | $6,204,000 | $3,530,000 | $5,130,000 |
| Cash Cash Equivalents And Short Term Investments | $112,943,000 | $169,454,000 | $203,057,000 | $241,054,000 |
| Cash And Cash Equivalents | $37,983,000 | $40,876,000 | $37,706,000 | $108,297,000 |
| Restricted Cash | - | $0 | $822,000 | $822,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $838,000 | $1,190,000 | $13,286,000 | $13,976,000 |
| Long Term Debt And Capital Lease Obligation | $435,000 | $838,000 | $12,434,000 | $13,448,000 |
| Current Debt And Capital Lease Obligation | $403,000 | $352,000 | $852,000 | $528,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $11,850,000 | $15,208,000 | $26,463,000 | $24,280,000 |
| Total Non Current Liabilities Net Minority Interest | $435,000 | $838,000 | $12,434,000 | $13,448,000 |
| Current Liabilities | $11,415,000 | $14,370,000 | $14,029,000 | $10,832,000 |
| Payables And Accrued Expenses | $6,480,000 | $9,013,000 | $8,679,000 | $7,407,000 |
| Payables | $3,155,000 | $6,579,000 | $3,237,000 | $2,996,000 |
| Accounts Payable | $3,155,000 | $6,579,000 | $3,237,000 | $2,996,000 |
| Equity | ||||
| Common Stock Equity | $104,712,000 | $176,080,000 | $225,689,000 | $246,028,000 |
| Total Equity Gross Minority Interest | $104,712,000 | $176,080,000 | $225,689,000 | $246,028,000 |
| Stockholders Equity | $104,712,000 | $176,080,000 | $225,689,000 | $246,028,000 |
| Gains Losses Not Affecting Retained Earnings | $84,000 | $139,000 | $224,000 | $-445,000 |
| Other Equity Adjustments | $84,000 | $139,000 | $224,000 | $-445,000 |
| Retained Earnings | $-446,454,000 | $-368,712,000 | $-310,003,000 | $-241,043,000 |
| Other | ||||
| Ordinary Shares Number | $53,331,766 | $51,935,134 | $51,445,862 | $45,771,332 |
| Share Issued | $53,331,766 | $51,935,134 | $51,445,862 | $45,771,332 |
| Tangible Book Value | $104,712,000 | $176,080,000 | $225,689,000 | $246,028,000 |
| Invested Capital | $104,712,000 | $176,080,000 | $225,689,000 | $246,028,000 |
| Working Capital | $103,812,000 | $161,288,000 | $193,380,000 | $236,174,000 |
| Capital Lease Obligations | $838,000 | $1,190,000 | $13,286,000 | $13,976,000 |
| Total Capitalization | $104,712,000 | $176,080,000 | $225,689,000 | $246,028,000 |
| Additional Paid In Capital | $551,082,000 | $544,653,000 | $535,468,000 | $487,516,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $435,000 | $838,000 | $12,434,000 | $13,448,000 |
| Current Capital Lease Obligation | $403,000 | $352,000 | $852,000 | $528,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,532,000 | $5,005,000 | $4,498,000 | $2,897,000 |
| Current Accrued Expenses | $3,325,000 | $2,434,000 | $5,442,000 | $4,411,000 |
| Investments And Advances | $0 | $13,843,000 | $25,505,000 | $2,495,000 |
| Net PPE | $1,038,000 | $1,552,000 | $19,048,000 | $20,494,000 |
| Accumulated Depreciation | $-1,327,000 | $-1,460,000 | $-3,270,000 | $-2,184,000 |
| Gross PPE | $2,365,000 | $3,012,000 | $22,318,000 | $22,678,000 |
| Leases | $81,000 | $51,000 | $10,765,000 | $409,000 |
| Other Properties | $801,000 | $1,143,000 | $8,382,000 | $19,739,000 |
| Machinery Furniture Equipment | $1,483,000 | $1,818,000 | $3,171,000 | $2,530,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $74,960,000 | $128,578,000 | $165,351,000 | $132,757,000 |
| Available For Sale Securities | - | $13,843,000 | $25,505,000 | $2,495,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-73,606,000 | $-51,937,000 | $-56,619,000 | $-71,744,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-73,577,000 | $-51,282,000 | $-55,657,000 | $-63,760,000 |
| Cash Flow From Continuing Operating Activities | $-73,577,000 | $-51,282,000 | $-55,657,000 | $-63,760,000 |
| Operating Gains Losses | $37,000 | $4,666,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-29,000 | $-655,000 | $-962,000 | $-7,984,000 |
| Investing Cash Flow | $70,172,000 | $53,352,000 | $-50,545,000 | $-1,368,000 |
| Cash Flow From Continuing Investing Activities | $70,172,000 | $53,352,000 | $-50,545,000 | $-1,368,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $35,121,000 | $0 |
| Financing Cash Flow | $505,000 | $313,000 | $35,577,000 | $958,000 |
| Cash Flow From Continuing Financing Activities | $505,000 | $313,000 | $35,577,000 | $958,000 |
| Net Common Stock Issuance | $0 | $0 | $35,121,000 | $0 |
| Common Stock Issuance | $0 | $0 | $35,121,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $37,983,000 | $40,876,000 | $38,528,000 | $109,119,000 |
| Beginning Cash Position | $40,876,000 | $38,528,000 | $109,119,000 | $173,289,000 |
| Effect Of Exchange Rate Changes | $7,000 | $-35,000 | $34,000 | $0 |
| Changes In Cash | $-2,900,000 | $2,383,000 | $-70,625,000 | $-64,170,000 |
| Proceeds From Stock Option Exercised | $505,000 | $313,000 | $456,000 | $958,000 |
| Net Investment Purchase And Sale | $70,170,000 | $53,756,000 | $-49,583,000 | $6,616,000 |
| Sale Of Investment | $158,373,000 | $202,042,000 | $170,956,000 | $235,815,000 |
| Purchase Of Investment | $-88,203,000 | $-148,286,000 | $-220,539,000 | $-229,199,000 |
| Net PPE Purchase And Sale | $2,000 | $-404,000 | $-962,000 | $-7,984,000 |
| Sale Of PPE | $31,000 | $251,000 | $0 | $0 |
| Purchase Of PPE | $-29,000 | $-655,000 | $-962,000 | $-7,984,000 |
| Change In Working Capital | $914,000 | $-1,592,000 | $5,427,000 | $-568,000 |
| Change In Payables And Accrued Expense | $-3,006,000 | $841,000 | $2,867,000 | $-1,708,000 |
| Change In Accrued Expense | $418,000 | $-2,501,000 | $2,632,000 | $-1,319,000 |
| Change In Payable | $-3,424,000 | $3,342,000 | $235,000 | $-389,000 |
| Change In Account Payable | $-3,424,000 | $3,342,000 | $235,000 | $-389,000 |
| Change In Prepaid Assets | $3,920,000 | $-2,674,000 | $1,723,000 | $-1,829,000 |
| Other Non Cash Items | $-72,000 | $-292,000 | $-370,000 | $243,000 |
| Stock Based Compensation | $5,924,000 | $8,872,000 | $12,375,000 | $10,195,000 |
| Amortization Of Securities | $-2,771,000 | $-5,371,000 | $-5,386,000 | $-628,000 |
| Depreciation Amortization Depletion | $133,000 | $1,144,000 | $1,257,000 | $315,000 |
| Depreciation And Amortization | $133,000 | $1,144,000 | $1,257,000 | $315,000 |
| Depreciation | $133,000 | $1,144,000 | $1,257,000 | $315,000 |
| Gain Loss On Sale Of PPE | $37,000 | $4,666,000 | $0 | $0 |
| Net Income From Continuing Operations | $-77,742,000 | $-58,709,000 | $-68,960,000 | $-73,317,000 |
| Change In Other Working Capital | - | $241,000 | $837,000 | - |
| Change In Other Current Liabilities | - | $241,000 | $837,000 | $2,969,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
Fetched: 2026-06-20